Results 101 to 110 of about 760 (154)

Resistance of <i>Acinetobacter baumannii</i> Complex Clinical Isolates to Sulbactam-Durlobactam: A Systematic Review of Data from In Vitro Studies. [PDF]

Pathogens
Falagas ME, Romanos LT, Ragias D, Filippou C.   +3 more
europepmc   +1 more source

Antibacterial activity of enmetazobactam against <i>Acinetobacter</i> spp.: a molecular dissection of mechanism of action and resistance determinants. [PDF]

Antimicrob Agents Chemother
Báez-Barroso G-A, Rodríguez-Coello A, Vázquez-Ucha JC, López-Argüello S, Outeda-García M, González-Pinto L, García-Pose A, Guijarro-Sánchez P, Alonso-García I, Lence E, González-Bello C, Oliver A, Arca-Suárez J, Moya B, Bou G, Beceiro A, Spanish National Acinetobacter spp. 2020 Study Group.   +16 more
europepmc   +1 more source

Loss-of-Function Mutations in the Penicillin-Binding Protein PonA1 Confer Agar-Dependent Resistance to Durlobactam in <i>Mycobacterium abscessus</i>. [PDF]

Antibiotics (Basel)
Negatu DA, Aragaw WW, Xie M, Dartois V, Dick T.   +4 more
europepmc   +1 more source

Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus [PDF]

Kurz, Sebastian Gerhard
core   +1 more source

From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem? [PDF]

Curr Opin Infect Dis
Bonazzetti C, Giannella M, Pascale R.
europepmc   +1 more source

Phenotypic Detection Methods, Clinical Outcomes, and Therapeutic Strategies for OXA-Type Carbapenemase-Producing Acinetobacter Species in an Indian Tertiary Care Setting. [PDF]

Cureus
Ullengala PR, Shinde RV, Patil SR.
europepmc   +1 more source

Sulbactam and Durlobactam Combination as a Newer Antibiotic for Carbapenem-Resistant Acinetobacter baumannii Infections

International Journal of Pharmaceutical Investigation
Sanatkumar Bharamu Nyamagoud, Agadi Hiremath Viswanatha Swamy, B J Abhishek, Leena Elizabeth Varghese, S K Bhoomika   +4 more
openaire   +1 more source

Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations. [PDF]

Infect Drug Resist
Gatti M, Pea F.
europepmc   +1 more source

Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies. [PDF]

Diagnostics (Basel)
Morena R, Gullì SP, Serapide F, Russo A.   +3 more
europepmc   +1 more source

Classification and applicability of new beta-lactamase inhibitors. [PDF]

Rev Esp Quimioter
Cercenado E, Candel FJ.
europepmc   +1 more source